NCT03038477View on ClinicalTrials.gov

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 12, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Pancreatic Cancer
Interventions
DRUG

Durvalumab

1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.

Trial Locations (1)

80045

University of Colorado, Aurora

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Colorado, Denver

OTHER